Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer
Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer
复制标题
辅助芳香酶抑制剂与绝经后乳腺癌女性白内障风险的关联。
DOI：
10.21037/atm.2020.02.112
复制
发表时间：
2020-03-01
影响因子：
--
通讯作者：
Xu, Ge-Zhi
中科院分区：
文献类型：
--
作者：
Chen, Han;Shao, Zhi-Ming;Xu, Ge-Zhi
背景：芳香酶抑制剂（AI）是绝经后激素受体阳性乳腺癌内分泌治疗的基础药物。 AI药物治疗与后续白内障风险之间的关系尚无定论。方法：纳入复旦大学附属肿瘤医院乳腺外科前瞻性数据库中的1,697例绝经后、早期、激素受体阳性乳腺癌患者，其中542例未接受内分泌治疗，1,155例仅接受AI治疗。我们探讨了是否使用AI以及AI持续时间对随后白内障发病率的影响。结果：整个研究人群中总共观察到146例（8.6%）白内障。白内障的发病率与年龄高度相关，60岁以下患者白内障的发病率分别为2.9%、6.9%和13.3%（P
Background: Aromatase inhibitor (AI) is a cornerstone drug for endocrine therapy of postmenopausal hormone receptor-positive breast cancer. The relationship between AI medication and subsequent cataract risk is yet inconclusive.Methods: A total of 1,697 postmenopausal, early-staged, and hormone receptor-positive breast cancer patients from the prospectively-maintained database of the Breast Surgery Department at Fudan University Shanghai Cancer Center were included, with 542 patients received no endocrine therapy and 1,155 treated with AI only. We explored the influence the use of AI or not and the duration of AI on the subsequent incidence of cataract.Results: A total of 146 (8.6%) cataracts were observed in the whole study population. The incidence of cataract is highly related to age, with incidence of cataract in patients = 60 years was 2.9%, 6.9%, and 13.3%, respectively (P